|
www.Xtremepicks.Com: Xtremepicks Alerts November 23, 2009 : CUTR, EDS, RVBD and SGEN
(M2 PressWIRE Via Acquire Media NewsEdge) Xtremepicks.com Alerts include Cutera, Inc. (Nasdaq: CUTR), Exceed Company Ltd. (NASDAQ: EDS), Riverbed Technology (NASDAQ: RVBD) and Seattle Genetics, Inc. (Nasdaq: SGEN)
Cutera, Inc. (Nasdaq:CUTR) trading at $9.20 per share on trading volume of 2,826 shares.
In a press release out on November 23, Cutera to Present at the Piper Jaffray 21st Annual Health Care Conference
BRISBANE, Calif., Nov 23, 2009 -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, announced today that Kevin Connors, the Company's Chief Executive Officer, will be presenting at the Piper Jaffray 21st Annual Health Care Conference on December 2, 2009 at 1:30 p.m. ET., at the New York Palace Hotel in New York, NY.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
Exceed Company Ltd. (NASDAQ: EDS) trading at $10.05 per share on trading volume of 43,000 shares.
In a press release out on November 23, Exceed Company Ltd. Announces Intent to Offer Program for Early Cashless Exercise of Warrants Through Ordinary Share Exchange
BEIJING, Nov 23, 2009 -- Exceed Company Ltd. ("Exceed" or the "Company") (NASDAQ: EDS), announced today that the Company intends to offer the holders of all 10,890,000 outstanding warrants (the "Warrants") the opportunity, for a limited time, to acquire ordinary shares of the Company (the "Ordinary Shares") through warrant for share exchange. Exceed intends to modify the terms of the Warrants to permit, instead of paying the purchase price of $5.25 in cash, the exchange of 3.96 Warrants for one Ordinary Share. The exchange ratio was determined by the board of directors of Exceed based on the ratio of the actual average daily closing prices of the Ordinary Shares and Warrants on NASDAQ for the period of November 9, 2009 to November 13, 2009.
ABOUT EXCEED COMPANY LTD
Exceed Company Ltd. designs, develops and engages in wholesale of footwear, apparel and accessories under its own brand, XIDELONG, in China. It is one of the leading domestic sports and leisurewear brands in China in terms of market share by sales revenue. Since operations began in 2002, Exceed has experienced significant growth in the mass market concentrated in the second and third tier cities in China and has established a market leading position as one of the top five Chinese sportswear brands. Exceed has three principal categories of products: (i) footwear, which comprises running, leisure, basketball, skateboarding and canvas footwear, (ii) apparel, which mainly comprises sports tops, pants, jackets, track suits and coats, and (iii) accessories, which mainly comprise bags, socks, hats and caps. Exceed Company Ltd. currently trades on Nasdaq under the symbols "EDS", "EDSWW" and "EDSUU".
Riverbed Technology (NASDAQ: RVBD) trading at $21.50 on a volume of 167,215 shares
In a press release out on November 23, Stena Drills Down to Reduce Bandwidth and IT Infrastructure Costs With Riverbed Steelhead Appliances
WAN Optimization Solution Cuts Costs While Improving Employee Productivity and Collaboration Over Satellite Network
SAN FRANCISCO, CA, Nov 23, 2009 -- Riverbed Technology (NASDAQ: RVBD), the IT infrastructure performance company for networks, applications and storage, today announced that Stena Drilling, a leading global provider and operator of offshore drilling rigs and drillships, has deployed Riverbed(R) Steelhead(R) appliances and Steelhead Mobile at various onshore and offshore locations worldwide. The deployment has allowed Stena to avoid both a costly bandwidth upgrade as well as additional investment in IT infrastructure. At the same time, Stena has seen a 30x improvement in file download times and enhanced staff collaboration.
About Riverbed
Riverbed Technology is the IT infrastructure performance company. The Riverbed family of wide area network (WAN) optimization solutions liberates businesses from common IT constraints by increasing application performance, enabling consolidation, and providing enterprise-wide network and application visibility -- all while eliminating the need to increase bandwidth, storage or servers. Thousands of companies with distributed operations use Riverbed to make their IT infrastructure faster, less expensive and more responsive. Additional information about Riverbed (NASDAQ: RVBD) is available at www.riverbed.com.
Seattle Genetics, Inc. (Nasdaq: SGEN) trading at $9.44 on a volume of 70,148 shares
In a press release out on November 23, Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration
BOTHELL, Wash. & SANTA MONICA, Calif., Nov 23, 2009 -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies' antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.
About Seattle Genetics
Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company's lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a special protocol assessment with the FDA. Brentuximab vedotin is empowered by Seattle Genetics' proprietary ADC technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. In addition, Seattle Genetics has four other product candidates in ongoing clinical trials: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70 and SGN-75. Dacetuzumab is being developed under a worldwide collaboration with Genentech (a wholly owned member of the Roche Group). Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech; Bayer; CuraGen, a subsidiary of Celldex Therapeutics; Progenics; Daiichi Sankyo; MedImmune, a subsidiary of AstraZeneca; and Millennium: The Takeda Oncology Company, as well as an ADC co-development agreement with Agensys, an affiliate of Astellas Pharma. More information can be found atwww.seattlegenetics.com.
Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.
Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To Contact Center Solutions Homepage's Homepage ]
|
NextiraOne Obtains Cisco's Unified Contact Centre Enterprise ATP Status 
EXTOL Appoints Michael DeCosta Vice President of Sales
NEW Consolidating Infrastructures: IT's New Call to Business [white paper]
